Cardiovascular
ApoB, Lp(a), atherosclerosis, prevention
01. Overview
Cardiovascular research here focuses on primary prevention, lipid biology, plaque progression, and the systems view of vascular aging. The best studies help prioritize biomarkers, therapies, and sequencing for long-horizon risk reduction.
Cardiovascular disease remains the dominant practical threat to lifespan, so this category emphasizes actionable prevention instead of reactive disease management.
Clinical theme
Atherosclerosis prevention
Clinical theme
Lipid optimization
Clinical theme
Inflammation and vascular damage
Clinical theme
Risk stratification
A clinical lens on cardiovascular research
Cardiovascular research is where the longest, largest trials live — read it for outcomes, not surrogates.
Use this topic to ground lipid, blood-pressure, and prevention strategy in actual outcome data.
- →ApoB and Lp(a) intervention review
- →Statin and PCSK9 evidence
- →Blood-pressure prevention strategy
- →Lifestyle vs pharma trade-offs
- Hard outcomes outweigh surrogate endpoints
- Statin data is robust and unfashionable to defend
- Lp(a) interventions are emerging
- Prevention beats reversal almost always
- What was the actual mortality signal?
- Is this surrogate or hard endpoint?
- Does it apply to my risk profile?
03. The Studies
0 indexedSample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation